Chordoma medical therapy

Jump to navigation Jump to search

Chordoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Epidemiology and Demographics

Risk Factors

Screening

Causes

Differentiating Chordoma from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chordoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chordoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chordoma medical therapy

CDC on Chordoma medical therapy

Chordoma medical therapy in the news

Blogs on Chordoma medical therapy

Directions to Hospitals Treating Chordoma

Risk calculators and risk factors for Chordoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

There are no drugs currently approved to treat chordoma, however chordoma has been shown to have a limited response to the PDGFR inhibitor Imatinib.[1]

References

  1. Casali PG, Messina A, Stacchiotti S; et al. (2004). "Imatinib mesylate in chordoma". Cancer. 101 (9): 2086–97. doi:10.1002/cncr.20618. PMID 15372471.


Template:WikiDoc Sources